We have performed whole genome expression profiling of 28 patient prostate tumor samples and 12 normal prostate samples and identified 55 upregulated and 60 downregulated genes significantly changed in prostate tumor samples compared to normal prostate tissues. Among the members of the upregulated gene set was the developmental transcription factor Homeobox C6 (HOXC6). Silencing of HOXC6 expression using small-interfering RNA (siRNA) resulted in decreased proliferation rates for both androgen-dependent LnCaP cells and the LnCaPderived androgen-independent C4-2 cell line. Flow cytometry and immunoblotting for the caspase-cleaved form of poly-ADP ribose polymerase (PARP) determined that the decrease in cell numbers was due to increased apoptosis. To validate the specificity of the siRNA-induced apoptosis, LnCaP cells were cotransfected with siRNA specific to the HOXC6 3 0 UTR and a mammalian expression vector containing the HOXC6 open reading frame, but lacking the 3 0 UTR. Overexpression of HOXC6 rescued the LnCaP cells from HOXC6 siRNA-induced apoptosis, and increased growth of control GFP siRNA-transfected cells. Expression profiling of HOXC6 siRNA transfections and HOXC6 overexpression identified neutral endopeptidase (NEP) and insulin-like growth factor binding protein-3 (IGFBP-3) as potential proapoptotic repression targets of HOXC6. Our data suggest that HOXC6 may be a novel potential therapeutic target for prostate cancer.
Introduction
Prostate cancer (PCa) is the most frequently diagnosed, noncutaneous neoplasm and the second leading cancerrelated death in American males (ACS, 2003) , and improved understanding of the molecular mechanisms involved in prostate tumor progression is critical to the development of more effective therapies. Oncogene overexpression has been implicated in the development and progression of a variety of human cancers (Felsher, 2003) , and one strategy for cancer therapy is the specific downregulation of oncogene expression. For years, research using antisense oligonucleotide strategy has met with limited success because of the lack of specificity and potency of this method (Braasch and Corey, 2002) . However, the recent discovery of gene silencing using small-interfering RNA (siRNA) provides a powerful new tool to target genes for deactivation (Elbashir et al., 2001) , and has the advantage of being delivered as small-molecule oligonucleotides to bypass the limitations of viral delivery-based antisense gene therapy.
Homeobox (HOX) genes are a family of at least 200 transcription factors that contain a highly conserved 61 amino-acid homeodomain that binds specifically to DNA (Stein et al., 1996) . First discovered in Drosophila as genes controlling segmentation and segment identity (Lewis, 1978) , HOX genes have been found in almost all metazoans. HOX family genes play key roles in development and differentiation, with some HOX genes expressed in the embryo, and others expressed in fully differentiated tissues. Alterations of HOX gene expression have been reported for many cancers, and in general, those HOX genes that are expressed in undifferentiated tissues are upregulated in tumors, while those HOX genes that are normally expressed in fully differentiated tissues are lost in tumors (Abate- Shen, 2002) . Both gains and losses of expression for a large variety of HOX genes have been reported in malignancies of the brain, breast, colon, kidney, lung, ovary, prostate, skin, and uterus (Abate- Shen, 2002) , and a translocation that produces an in-frame fusion of the nucleoporin gene NUP98 with the HOXA9 gene is associated with myeloid leukemia (Nakamura et al., 1996) . Expression of NKX3.1, a HOX transcriptional repressor that is normally expressed in fully differentiated prostate tissues, is lost in many prostate cancers (Bowen et al., 2000) . The gene encoding NKX3.1 resides at 8p21, a region that undergoes frequent loss of heterozygosity in prostate tumors (Chen et al., 2002) . Aged mice lacking the NKX3.1 gene display histopathological defects resembling prostatic intraepithelial neoplasia (PIN), suggesting that NKX3.1 plays a role in the early stages of prostate carcinogenesis (Kim et al., 2002a) . Moreover, loss of NKX3.1 can cooperate with loss of PTEN to produce increased high-grade PIN (HGPIN) in double mutant mice (Kim et al., 2002b) . Conditional loss of NKX3.1 in adult mice leads to PIN lesions (Abdulkadir et al., 2002) , and haploinsufficiency of NKX3.1 extends the proliferative stage of regenerating luminal prostatic epithelial cells, leading to hyperplasia (Magee et al., 2003) . Thus, loss of NKX3.1 appears to be important for the very early steps of PCa formation.
In humans, there are 39 classical HOX genes organized into four clusters (A, B, C, and D) that are localized on chromosomes 2, 7, 12, and 17. Recently, HOXC gene cluster overexpression was observed in LnCaP cells, lymph node metastases, and primary tumor cells using reverse-transcription PCR techniques (Miller et al., 2003) . Increases in HOXC6 expression have been detected in osteosarcomas (Bodey et al., 2000d) , medulloblastomas (Bodey et al., 2000c) , and carcinomas of the breast (Bodey et al., 2000b) , lung (Bodey et al., 2000a) , and prostate (Ernst et al., 2002) . HOXC6 has been shown to both repress (Chariot et al., 1996) and activate (Jones et al., 1993) transcription, but the mechanism by which HOXC6 activates some genes and represses others is not well understood. There are two alternatively spliced HOXC6 mRNA species: HOXC6-1, a 1.8 kb transcript (clone 211; NM_004503) that encodes a 27 kDa protein (Chariot et al., 1996) , and HOXC6-2, a 2.2 kb transcript (clone 173; NM_153653) that encodes an 18 kDa protein. HOXC6 is also expressed in the human breast cancer cell line MCF7 (Castronovo et al., 1994) , in the HeLa cervical cancer line (our unpublished data), and we show here that HOXC6 is expressed in the LnCaP, C4-2, DU145, and PC3 PCa lines. Expression of HOXC6 is hormonally regulated, and is repressed specifically in mammary stroma in response to estrogen and progesterone (Garcia-Gasca and Spyropoulos, 2000) . Importantly, in HOXC6 À/À null mice, 100% of females show complete absence of mammary epithelium in thoracic glands and dilated ducts in inguinal glands (Garcia-Gasca and Spyropoulos, 2000) . Thus, HOXC6 is crucial to the development and proliferation of epithelial cells in response to hormonal signals. However, the biological effects of perturbing HOXC6 expression in PCa cells are unknown.
In this study, we have performed whole genome expression profiling of 28 patient prostate tumor samples and 12 normal patient prostate samples and determined that 55 genes, including the developmental transcription factor HOXC6, are significantly overexpressed in prostate tumor samples, while 60 genes were significantly underexpressed. Transfection of the androgen-dependent LnCaP cell line and the androgenindependent C4-2 cell line with siRNA duplexes complementary to the HOXC6 genes resulted in strongly decreased cell viability and induction of apoptosis. Rescue experiments using overexpression of HOXC6 demonstrate the specificity of the siRNAinduced apoptotic effect. We also identified several repression targets of HOXC6 by expression profiling of LnCaP transfections, including the proapoptotic genes NEP and IGFBP-3. These data suggest that HOXC6 may help prevent apoptosis of PCa cells by repressing NEP and IGFBP-3 expression, and that HOXC6 may be a novel therapeutic target for PCa.
Results

Prostate cancer patient expression profiling
To identify changes in gene expression correlated with PCa progression, we have undertaken whole genome expression profiling of PCa patients. We have prepared total RNA by trizol extraction of serial sections from snap-frozen tissues and performed global gene expression profiling on 28 PCa patients with Gleason scores ranging from 6 to 9. To date, we have profiled 28 tumor patient samples, 11 adjacent normal patient samples, and a commercial pool of normal prostate RNA (ClonTech) using Affymetrix U133 GeneChip array sets, which cover the entire human genome and contain probes representing approximately 39 000 transcripts. The 11 adjacent normal samples correspond to normal prostate tissue taken from the same frozen sections as 11 of the prostate tumor specimens. After data normalization, we have looked for genes that are differentially expressed between tumor and normal samples in a statistically significant manner. To compensate for multiple testing issues associated with an array set that queries 39 000 transcripts, we have used the Significance Analysis of Microarrays (SAM) software (Tusher et al., 2001) , which computes false discovery rates (FDRs) for any user-specified threshold (D) for statistical stringency and fold-change. Using a highly conservative threshold that provided a median estimate of less than two falsepositive genes, the SAM analyses identified 63 upregulated and 80 downregulated probe sets that were significantly different between prostate tumor and normal tissues (q-value o0.015; Figure 1a ). The 63 upregulated probe sets corresponded to 55 unique genes, and the 80 downregulated probe sets corresponded to 60 unique genes for a total of 115 unique genes. Figure 1b shows the normalized expression levels for the 143 significantly altered probe sets. In agreement with Ernst et al. (2002) one of these 55 significantly upregulated genes was the HOX transcription factor HOXC6. To verify our microarray data by alternative methods, we used quantitative real-time polymerase chain reaction (QRT-PCR) to measure the mRNA levels of HOXC6 in RNA prepared from PCa tumor samples and matched normal adjacent tissue (Figure 1c) . Although QRT-PCR measures larger changes in expression than microarrays, Figure 1c shows good agreement in the fold increase of tumor vs normal RNA samples as measured by both microarray (1.7-fold increase) and QRT-PCR analyses (4three-fold increase).
Global analysis of HOX gene expression
Recent reports have found upregulation of other members of the HOXC cluster (Miller et al., 2003) , prompting us to more closely examine the gene expression patterns for all HOX family genes. Figure 2a shows a heat map of the log2 transformed, RMA normalized signals of all HOX genes present on Affymetrix U133A and U133B GeneChips. An examination of the expression levels of HOX family genes shows that HOXA10, HOXA11, HOXA13, HOXB1, HOXB2, HOXB4, HOXB5, HOXB9, HOXB13, HOXC4, HOXC5, HOXC11, HOXD1, and HOXD13 are all expressed in both normal and cancerous prostate tissues to varying degrees. However, HOXC6 (arrow) is the only HOX gene that is consistently upregulated in PCa tissues compared to normal prostate tissues as measured by microarray analysis. The HOXD9 and HOXD10 genes were both downregulated in PCa tissues, and HOXD10 downregulation was statistically significant as determined by SAM analysis.
To confirm that the increase in HOXC6 expression is also seen at the protein level, we developed polyclonal antisera to HOXC6 directed against KLH-linked peptides that are highly specific to HOXC6. We used these polyclonal antisera to probe immunoblots of lysates from normal primary prostate epithelial cells (PrEC) (Cambrex Bio Science), and the PCa cell lines PC3, LNCaP, DU145, and C4-2 ( Figure 2b ). HOXC6 expression was increased at the protein level in all PCa cell lines tested. These data, together with the observation that HOXC6 was the only HOX gene significantly upregulated in PCa tissues, prompted us to determine the effects of specific repression of HOXC6 expression in PCa cell lines.
HOXC6 siRNA induces apoptosis in LnCaP and C4-2 cells
To determine the effect of loss of HOXC6 in both androgen-dependent and androgen-independent PCa cells, we designed six siRNA duplexes complementary to both isoforms of HOXC6 ( Figure 3a) . One of these siRNA duplexes (H2) was in the open reading frame (ORF) of both isoforms, four were in the 3 0 untranslated region (3 0 UTR) of both isoforms (H3, H4, H5, and H7), and the H1 siRNA was in the 5 0 UTR of the HOXC6-2 isoform and the ORF of the HOXC6-1 isoform. We performed transient siRNA transfections using pools of five HOXC6 siRNA duplexes (H1-H5) in the androgendependent LnCaP and LnCaP-derived, androgen-independent C4-2 cell lines, and prepared total RNA and whole cell protein lysates at 48 h post-transfection. Parallel transfections using siRNA directed against Lamin A/C were used as a positive control and against green fluorescent protein (GFP) were used as a negative control. Specific repression of HOXC6 was assayed by QRT-PCR and immunoblotting with our own HOXC6 polyclonal antisera. Although the probe sets on the Affymetrix U133 DNA microarrays cannot distinguish between the long and short isoforms of HOXC6 mRNAs, our three sets of QRT-PCR primers are specific to the HOXC6-1 and HOXC6-2 isoforms, or can measure both transcripts. Using siRNA duplexes complementary to both isoforms of HOXC6, we successfully repressed the mRNA and protein expression of both HOXC6-1 and HOXC6-2 isoforms in LnCaP cells at both the mRNA (Figure 3b ) and the protein levels ( Figure 3c ). Similar transfections in C4-2 cells demonstrated repression at the mRNA ( Figure 4a ) and protein levels as well ( Figure 4b) .
By 48 h post-transfection, HOXC6 siRNA experiments consistently produced about a two-fold lower yield of total protein lysate and five-fold lower yield of total RNA than the GFP control siRNA-treated LnCaP cells, suggesting that there may be decreased growth or increased cell death in HOXC6 siRNA-treated cells. Consequently, we measured cell viability by trypan blue dye exclusion after HOXC6 siRNA transfection over a timecourse of 5 days. HOXC6 siRNA significantly (Po0.05) inhibited cell proliferation in the LnCaP ( Figure 5a ) and C4-2 cells (Figure 5b ) when compared to the GFP-transfected cells.
Large numbers of floating, dead cells were present in the culture medium after 48 h of siRNA treatment, suggesting that loss of HOXC6 expression is lethal to the LnCaP and C4-2 PCa cells. To evaluate the extent of change in cell cycle, cell lysates were prepared at 0, 48, and 96 h post-transfection with HOXC6 siRNA, stained for DNA content with propidium idodide, and analysed by flow cytometry. The sub-G0/G1 population of cells at 48 h post-HOXC6 siRNA transfection was about (Figure 5c ), and 1.6-fold greater in the C4-2 cells (Figure 5d ) when compared to the GFP control. But by 96 h, the apoptotic cell population was 2.5-fold greater in the HOXC6 siRNA-transfected LnCaP cells, and 1.8-fold greater in the C4-2 cells when compared to GFPtransfected cells. The HOXC6 siRNA-induced apoptosis was further confirmed by immunoblots probed for cleaved PARP, a marker of apoptosis, which increased in a time-dependent manner (data not shown). Moreover, the magnitude of the siRNA-induced apoptosis was strongly correlated with the level of HOXC6-specific repression at both the mRNA (R 2 ¼ 0.92; Figure 5e ) and protein levels (R 2 ¼ 0.97; Figure 5f ).
Overexpression of HOXC6-1 or HOXC6-2 rescues LnCaP cells from HOXC6 siRNA-induced apoptosis
To demonstrate that the HOXC6 siRNA-induced apoptosis was specific, we tested whether overexpression of HOXC6 rescues LnCaP cells from siRNA-induced apoptosis. Consequently, we cotransfected pcDNAHisA-HOXC6-1 and pcDNA-HisA-HOXC6-2 expression vectors lacking 3 0 UTR sequences, or the empty vector alone (pcDNA-HisA) with either GFP control siRNA or siRNA specific to the 3 0 -UTR of HOXC6 (H3-H5). Transfected LnCaP cells were assayed for viability and apoptosis at 48 h post-transfection. There was a 43 and 39% reduction in the number of viable cells in the HOXC6 siRNA-treated and HOXC6 siRNA þ vector alone treated cells, respectively, when compared to GFP siRNA-treated cells (Figure 6a ). There was a commensurate increase in apoptotic cells in the HOXC6 siRNA-treated (11.6%) and HOXC6 siRNA þ vector alone (12%) treated cells (Figure 6b) . Importantly, overexpression of HisA-HOXC6-1 in HOXC6 siRNA-transfected cells exhibited similar levels of apoptosis as cells treated with control GFP siRNA duplexes (Figure 6b ). While HOXC6-2 expression was less effective than HOXC6-1 at rescue from apoptosis (Figure 6b) , there was an intermediate increase in the number of viable cells cotransfected with HOXC6 siRNA and HOXC6-2 (Figure 6a ). In addition, we observed a significant reduction in the rate of apoptosis in the GFP siRNA þ HisA-HOXC6-1-treated cells. For an independent measure of apoptosis, protein lysates at 48 h post-transfection were prepared, and immunoblots were probed with a monoclonal antibody to the cleaved form of poly-ADP ribose polymerase (cleaved PARP), a well-characterized caspase substrate. Immunoblotting determined that HOXC6-siRNA transfected LnCaP cells have increased levels of cleaved PARP, suggesting that they undergo apoptosis (Figure 6c ). Decreased expression of cleaved PARP in HOX siRNA þ HisA-HOXC6-1-treated cells when compared to the HOXC6 siRNA-treated cells also demonstrates that HOXC6 siRNA-induced apoptosis is specific (Figure 6c ). In summary, overexpression of HOXC6 rescued LnCaP cells from HOXC6 siRNA-induced apoptosis, and also increased the growth of GFP siRNA-transfected cells.
HOXC6 represses NEP/MME and IGFBP-3 genes involved in apoptosis
To identify the targets of HOXC6 that are relevant to apoptosis and to determine whether they overlap with the 115 genes that we found altered in PCa patient tissues, we performed transient HOXC6 siRNA and overexpression experiments in LnCaP cells. Total RNA was prepared from cells transfected with pcDNA3-HOXC6-1 plus GFP siRNA, pcDNA vector plus HOXC6 siRNA H7, and pcDNA vector plus GFP siRNA as controls. Independent biological replicates were then analysed using Affymetrix U133AB Array sets, and HOXC6 was determined to be the only HOX family gene significantly repressed by HOXC6 siRNA (Figure 7a ). HOXC6 activation and repression targets were identified by SAM analysis using a median FDR of 3% and 1.7 fold-change cutoff (Figure 7b ), and five of these targets were confirmed by QRT-PCR (Figure 7c ). The only gene that was both upregulated significantly in our PCa patient expression data and induced significantly by HOXC6 was the T-Cell Gamma chain constant region (TRGC2), which encodes the T-cell receptor alternate reading frame protein (TARP). TARP encodes a 7 kDa nuclear protein with a leucine zipper motif, basic domain, and a WD40 repeat that shares homology with the yeast TUP1 repressor (Wolfgang et al., 2000) , suggesting that it could mediate repression of target genes. Moreover, TARP is highly expressed in breast and prostate cancers (Essand et al., 1999) , is regulated by androgen , and overexpression of TARP leads to increased growth rate of PCa cells (Wolfgang et al., 2001) . Two proapoptotic genes, IGFBP-3 and NEP/MME, were both downregulated in patient expression data and repressed significantly by HOXC6. MME (membrane metallo-endopeptidase) is also known by the alternative names neutral endopeptidase (NEP), enkephalinase, CALLA, and CD10. NEP/MME proteolizes neuropeptides such as endothelin-1 (ET-1) and bombesin, which promote PCa cell survival by activation of the IGF-I receptor and the Akt kinase (Sumitomo et al., 2001) . NEP/MME also promotes phorbol ester-induced apoptosis in LnCaP cells by inhibiting c-Src kinase activity and protein kinase C d (PKC d) degradation . NEP/MME expression is also regulated by androgens and has ARE elements in its promoter . NEP/MME can induce apoptosis in MCF7 breast cancer cells and inhibit proliferation of DU145 PCa cells (Firth and Baxter, 2002) .
Like NEP/MME, insulin-like growth factor binding protein-3 (IGFBP-3) antagonizes IGF signaling. Although IGFBP-3 did not meet the significance criteria of q-value o0.03 and fold change 41.7 for the probe sets from patient expression data shown in Figure 1b , it was significantly downregulated in patient tumors if a value of qo0.05 was used. In addition, IGFBP-3 has been shown by others to exhibit decreased expression in some laser-capture microdissected prostate cancers (Thelen et al., 2004) . IGFBP-3 mediates the apoptotic (Rajah et al., 1997) and growth inhibitory effects of TGF-b (Fanayan et al., 2000) , and consequently repression of IGFBP-3 by HOXC6 may be important in resistance to TGF-b growth suppression of some prostate cancers. Moreover, IGFBP-3 is induced by p53 and mediates p53-dependent apoptosis (Grimberg et al., 2002) . Thus, HOXC6 modulates the expression of multiple genes that are significantly altered in patient prostate tumors, and represses the expression of two proapoptotic genes, NEP/MME and IGFBP-3. Whether this repression is direct or indirect via TARP or some other intermediate effector molecule(s) cannot be determined from these data, but will be of interest in future studies.
Discussion
HOX transcription factors are essential for embryonic development and play critical roles in cell fate determination, differentiation, and proliferation. Overexpression of HOX genes can transform mammalian cells in vitro and in vivo (Aberdam et al., 1991; Maulbecker and Gruss, 1993) , and increased HOX gene expression has been detected in many cancer types (Cillo, 1994) . A recent report detected overexpression of HOXC cluster genes in prostate cancers (Miller et al., 2003) . Our global expression profiling of 40 prostate normal and tumor tissue samples has determined that HOXC6 is significantly overexpressed in PCa, in agreement with earlier reports (Ernst et al., 2002) . Using siRNA approaches, we have shown that loss of HOXC6 expression can induce apoptosis in both LnCaP and C4-2 PCa cell lines, and that this effect can be reversed by overexpression of HOXC6.
Both antisense (DeYoung et al., 2003) and siRNA (Yoshinouchi et al., 2003) approaches have been used to successfully attenuate the growth of cancer cells in vitro and in vivo. Our results demonstrate that HOXC6 siRNA can effectively downregulate HOXC6 overexpression in the LnCaP and C4-2 cells with great specificity. The siRNA suppression of HOXC6 expression was more effective in the LnCaP cells than in the C4-2 cells, and the efficiency of knockdown correlated with the strength of the apoptotic effect. This differential response could be due to differences in transfection efficiency, p53 status, or possibly in the siRNA machinery in C4-2 cells. However, the latter possibility is less likely, since Lamin A/C positive control siRNA transfections effectively inhibited Lamin A/C expression in C4-2 cells (Figure 4b) .
Several of the genes that we found significantly affected by HOXC6 levels are also regulated by androgen receptor (AR) signaling. Thus, it appears that HOXC6 modulates AR-stimulated gene expression, but in the context of some promoters (e.g. TARP) HOXC6 can enhance activation by AR, while in other promoter contexts (e.g. SOX4, MME/NEP), HOXC6 can inhibit activation by AR. HOXC6 could directly compete for occupancy of promoters that are regulated by AR, or alternatively, HOXC6 repression could be mediated indirectly via TARP activation, or through a HOXC6-TARP complex. Moreover, HOXC6 repressed expression of filamin A (FLNA), a cytoplasmic crosslinker of actin filaments. Recently, it has been shown that a naturally occurring C-terminal 100-kDa fragment of FLNA interacts with the AR hinge domain, colocalizes with AR to the nucleus, disrupts interactions between the AR ligand binding-and trans-activation domains, and specifically represses AR transactivation (Loy et al., 2003) . Thus, by repressing expression of FLNA, HOXC6 may be indirectly enhancing AR activity, and promoting cell survival.
At least two HOXC6 targets (IGFBP-3 and PA26) are regulated by the p53 tumor suppressor. IGFBP-3 is induced by p53 and mediates p53-dependent apoptosis (Grimberg et al., 2002) , while PA26 is a member of the GADD family of DNA damage and growth arrest inducible genes (Velasco-Miguel et al., 1999) . In addition, vitamin D induced arrest of PCa cell growth is mediated through IGFBP-3 and induction of the p53 target p21 (Krishnan et al., 2003) . Thus, IGFBP-3 suppression by HOXC6 may be more important in p53 wt LnCaP cells and earlier stage prostate cancers to prevent p53-dependent apoptosis than in more later stage prostate cancers and p53 -/-PC3 cells. The repression of SOX4 by HOXC6 (Figure 7b ) is interesting and is consistent with the observation that HOXC6 expression drops in metastatic PCa, while SOX4 expression is increased in metastatic disease (Dhanasekaran et al., 2001) . One hypothesis to explain this pattern of PCa progression would be that HOXC6 expression is important in p53 wt cancers to prevent p53-dependent apoptosis, but if p53 becomes inactivated via other mechanisms, HOXC6 expression can be lost, resulting in even higher SOX4 expression. What is not yet clear is whether HOXC6 prevents activation of p53 or the activation of p53-target genes, or whether the apoptosis in HOXC6 siRNA-treated cells is dependent on p53, IGFBP-3, and/or NEP/MME.
The rescue experiments using cotransfection of the HOXC6 siRNA and HOXC6 cDNAs and the expression profiling of siRNA transfections demonstrated that the biological effects of siRNA-induced knockdown HOXC6 expression were indeed specific to HOXC6, and that either of the HOXC6 isoforms could rescue cells from apoptosis and stimulate cell growth. However, the 27 kDa HOXC6-1 isoform appeared to be more effective than the smaller 18 kDa HOXC6-2 isoform at apoptotic rescue (20 vs 10% decrease). Our results provide support for a model of prostate tumorigenesis that includes loss of NKX3.1 in HGPIN for initial loss of terminal differentiation and progresses to early stage PCa with increased expression of HOXC6 to induce an undifferentiated and highly proliferative state. Mechanisms by which HOX genes alter the cell cycle and proliferative capacity of cells include upregulation of cyclin D1 (Hu et al., 2001) and interference with G2/M checkpoint (Kawabe et al., 1997) . Recently, a study in chick embryos found that overexpression of HOXB7 or HOXA11 can disrupt complexes of geminin and Cdt1, suggesting that HOX proteins can directly promote initiation of DNA replication and S-phase progression independent of transcriptional activation (Luo et al., 2004) . Moreover, a repression target of HOXC6 identified in this study was PI3KR3 (Figure 7b) , the p55g regulatory subunit of phosphoinositide-3-kinase (PI3 K), which can bind to the retinoblastoma (Rb) Figure 7 (a) Expression profiling of all HOX family genes in HOXC6 siRNA transfections of LnCaP cells. The only downregulated HOX gene is HOXC6 (arrowhead). (b) Expression profiles of genes significantly altered in PCa and by perturbation of HOXC6 mRNA levels. Four probe sets corresponding to the Tcell receptor gamma constant region all measure the same TCRg alternate reading frame protein (TARP). IGFBP-3 is the only HOXC6 target shown that did not meet the criteria of q-value o0.03 and fold change 41.7 for the probe sets shown in Figure 1b (see text). (c) QRT-PCR of LnCaP cells transfected with HOXC6 siRNA, pcDNA3-HOXC6-1, or vector control. The average and s.e. of three independent experiments is shown for mRNA fold change relative to control GFP transfections. Changes in response to altered HOXC6 levels were confirmed for TARP, IGFBP-3, NEP/MME, FLNA, and SOX4
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Our data also suggest that HOXC6 may be a novel potential therapeutic target for human PCa. Identification of regulatory targets of HOXC6 has provided insights into the mechanisms by which this transcription factor alters the behavior and survival of PCa cells, and suggests that targeting of HOXC6 provides an opportunity to interfere with IGF survival signaling of PCa cells at multiple levels. Although the distribution was fairly heterogeneous among the 28 tumor samples in this study, 22 (79%) had HOXC6 overexpression identified in their cancer foci with an average increase of two to three-fold. This is a smaller increase than a previous study (Ernst et al., 2002) of 17 tumor and nine normal samples in which HOXC6 was increased on average eight-fold, and was found to be the third most increased transcript out of 12 600 sequences. We would speculate that up to 50-80% of low-grade (Gleason sum 6 or 7) PCa patients could theoretically benefit from therapies directed at HOXC6. It is even possible that patients without HOX6C overexpression would respond to such therapies since overexpression is not a prerequisite for significant transcription factor activity on downstream targets. Critical to the success of siRNA as a cancer therapy will be the ability to obtain highly efficient modes of transfection of cancer cells. Nevertheless, if such high efficiency can be achieved, there should be little to no effect on nonprostate bystander cells, since they do not express HOXC6. Future work to examine the effectiveness of HOXC6 siRNA on PCa in preclinical animal models will help determine whether this approach represents an avenue for clinical trials.
Materials and methods
Cell lines
The LnCaP, C4-2, DU145, and PC3 PCa cell lines were a generous gift from Dr Lelund Chung, Winship Cancer Institute, Emory University School of Medicine. These cells were maintained in T-medium containing 10% fetal bovine serum at 371C and 5% CO 2 . Normal human prostate epithelial cells (PrEc cells) were obtained commercially (Cambrex Bio Science, Walkersville, MD, USA) and maintained in PrEGM TM -Prostate Epithelial Cell Medium according to the supplier's protocols.
Patient samples
All patients enrolled had biopsy-proven PCa and had undergone radical prostatectomy at Emory University affiliated hospitals. Cases were chosen at random from 1999 to 2002. Histologic confirmation was obtained in all cases and dissection of cancer foci was performed to assure that at least 90% of cells collected were malignant epithelial cells. Eight of the tumor samples had Gleason grade sum of 6, 17 had Gleason grade sum of 7, two had a Gleason grade sum of 8, and one sample had a Gleason grade sum of 9.
Microarray analysis
Total RNA was prepared by trizol extraction of serial sections from snap-frozen tissues. For each frozen specimen of prostate, one frozen section was stained with hematoxylin and eosin (H&E) to map areas of carcinoma and nonneoplastic prostate, after which 15-mm thick serial sections were cut for isolation of total RNA. Trizol reagent (50 ml) was dispensed onto an area of interest on the frozen section and pipetted up and down several times to solubilize tissue. Surrounding tissue on the frozen section was avoided in order to isolate RNA selectively from either cancer or non-neoplastic tissue. Pooled extracts from 10 to 15 serial sections typically produced 1-3 mg total RNA after trizol extraction. RNA was reverse transcribed to DNA, transcribed in vitro with the Enzo biotin labeling kit, and cRNA fragmented according to the Affymetrix standard protocols. cRNA probes were hybridized overnight to the Human Genome U133 GeneChip set, washed in a GeneChip Fluidics Workstation, and scanned according to the manufacturer's protocols. Data were analysed using the Affymetrix Microarray Suite 5.0 (MAS 5.0) software to filter out genes that were called present in fewer than 50% of normal and tumor hybridizations, reducing the number of probe sets considered from 44 929 to 15 031. In addition, Affymetrix CEL files were normalized using the robust multiarray average (RMA) method (Bolstad et al., 2003) encoded in the Bioconductor package (www.bioconductor.org) for the R statistical programming environment (www.r-project.org). After data normalization, SAM analysis was performed on RMA-normalized data for the remaining 15 031 probe sets as two class, unpaired data (tumor and normal), using the 10-Nearest Neighbor Imputer engine and the following relevant parameters: D ¼ 0.93, fold-change ¼ 1.7, number permutations ¼ 600, RNG seed ¼ 1234567, median FDR ¼ 1.46%, significant genes ¼ 143, predicted false positives ¼ 2. Heat maps were generated using Spotfire DecisionSite 7.2 for Functional Genomics.
siRNA design and transient transfection siRNA duplexes were designed, synthesized, annealed, and purified (MWG Biotech, NC). Optimal transfection of LnCaP and C4-2 cells was obtained with a combination of five different siRNAs to HOXC6 used as a cocktail at a final concentration of 100 nM. All siRNA sequences were subjected to BLAST search to confirm the absence of homology to any additional known coding sequences in the human genome. The  HOXC6 0 . Lamin and GFP siRNA were standard siRNAs procured from MWG Biotech. Transient siRNA transfections were performed using DMRIE-C (Invitrogen, CA, USA) for PCa cells in six-well plates. At the end of 48 h, cells were harvested for total RNA isolation and protein lysate for immunoblots, flow cytometry, and viability assays. Protein lysates were prepared as described (Moreno et al., 2000) , and total RNA was prepared using RNeasy kits (Qiagen, CA, USA) according to the manufacturer's instructions.
Cotransfection experiments
To validate the specificity of the siRNA-induced apoptosis, LnCaP cells were cotransfected with siRNA specific to the HOXC6 3 0 UTR, and a mammalian expression vector containing the HOXC6 open reading frame, but lacking the 3 0 UTR (Wei and Pallas, 2003) . Clones of both isoforms of the human HOXC6 gene were a generous gift of Dr Alain Chariot (Chariot et al., 1996) . PCR primers with BamH1 and Xho1 sites were designed to enable amplification of the HOXC6-1 and HOXC6-2 ORFs with start ATG with BamH1, and stop TGA with Xho1 sites introduced at the 5 0 and 3 0 ends, respectively. PCR primer sequences were 5 0 TAGAGGATC CAGGTAAAGGCAAAGGGATGA 3 0 and 5 0 GAGAACT CGAGAGAGGGGTGGCAGGGACAG 3 0 for HOXC6-1 and 5 0 TCCTGGATCCAGGAGAAAGACATGCTCTC 3 0 and 5 0 ACAGCTCGAGTCACTCTTTCTGCTTCTCCTCTT CT 3 0 for HOXC6-2. PCR amplification products were digested with BamH1 and Xho1, and were cloned in frame with an N-terminal Xpress epitope using the pcDNA3.1-HISA vector (Invitrogen). Cotransfection experiments were carried out in LnCaP cells in six-well plates with siRNA (100 nM) in combination with and without HOXC6 DNA (4 mg) for 48 h.
Quantitative real-time PCR
To confirm decrease in HOXC6 at the mRNA level, total RNA was harvested 48 h post-transfection, cDNA synthesized by reverse transcription (PowerScript, ClonTech), and transcript levels quantitated by QRT-PCR using SYBR Green (Molecular Probes). Cycle threshold differences were quantitated on an I-cycler Bio-Rad, Hercules, CA, USA) relative to b-actin to control for total starting RNA levels in each cell line, and experiments were performed on three separate days in duplicate. Although the probe sets on the Affymetrix U133 DNA microarrays cannot distinguish between the long and short isoforms of HOXC6 mRNAs, our QRT-PCR primer sets were designed specific to the HOXC6-1 (sense: 5 0 GTTCCGAGTACAAACTGGAGACAG 3 0 ; antisense: 5 0 TG GCAGGATAAGGAAGGGTTAGTG 3 0 ) and HOXC6-2 (sense: 5 0 TATGTGTGTGTGTGTGGAGCTGAG 3 0 ; antisense: 5 0 TCTCTCTCCCACTCTCTTTCTCGT 3 0 ) isoforms, or can measure both transcripts of HOXC6 (sense: 5 0 TCC TCTTCTGTCTCTTCCCGC 3 0 ; antisense: 5 0 TTCTCCAGTT CCAGGGT 3 0 ). b-Actin primers were sense 5 0 CTGGAAC GGTGAAGGTGACA 3 0 ; antisense 5 0 AAGGGACTTCC TGTAACAATGCA 3 0 .
Western blots
Immunoblots were probed with monoclonal antibody to Lamin A/C (Santa Cruz Biotech) and polyclonal antisera to HOXC6. We synthesized three synthetic peptides specific to HOXC6 (ATADSLGGKEEKREETEEEKQKEC, SEQGR-TAPQDQKASC, and GSNSFYQEKDMLSNC), linked them to keyhole limpet hemocyanin (KLH) with maleimide-activated KLH (Pierce Inc., IL, USA), and raised polyclonal rabbit antisera (Rockland Inc., PA, USA). Blots were later probed using a monoclonal antibody to PP2A catalytic subunit (BD Transduction Labs, CA, USA) to normalize for equal protein loading. Immunoblots were quantitated using a Bio-Rad Fluor-S Max chemilumimager, which has a linear range of almost five orders of magnitude.
Cell viability assay
At the end of the 48 h post-transfection, both the attached and floating cells were harvested, spun and the pellet made up to a known volume with regular media. Cell viability was measured by hemocytometer cell counts using the trypan blue dye. Live cells exclude the dye, and results were expressed as % viability.
Apoptosis assay
Apoptosis levels in transient siRNA transfections against HOXC6 were quantitated by immunoblotting with a monoclonal antibody (Cell Signaling, Inc.) . that is specific for the cleaved form of poly-ADP-ribose polymerase (PARP), a substrate of caspase 3. Mock transfections served as a negative control.
Flow cytometry
The percent of cells undergoing apoptosis and the different phases of the cell cycle were determined by flow cytometry. At appropriate times after the siRNA treatment, floating and attached cells were harvested, washed twice with ice-cold PBS and fixed in ice-cold 70% ethanol overnight at À201C. Fixed cells were washed, stained with propidium iodide, and the number of cells with less than 2 N DNA content was quantitated by fluorescence-activated cell sorting (FACS) analysis. The percentage of cells in sub-G0/G1, G0/G1, S and G2/M phases were determined using the Cell Quest software (Becton Dickinson, CA, USA). Apoptotic cells were defined as those cells in the sub-G0/G1 (o2 N DNA) peak.
Statistical analysis
Results are expressed as mean7s.d. Statistical comparisons are evaluated by Student's t-test and the significance was set as Po0.05.
